Biotech Values

[RockRat]

ACHN also reported some early data for C3G. n=2 and open label, but signal was good enough to demonstrate proof of concept and move along. I have a position, and think this may be a good time to add on the weakness. With the Hep C program dead and the J&J overhang gone, this is an interesting play on their complement factor D inhibition program.

Regards, RockRat